BioLineRx (BLRX) Return on Capital Employed (2013 - 2025)
BioLineRx (BLRX) posted Return on Capital Employed of 36.44% for Q4 2025, up 10.36% on a QoQ basis from 40.65% in Q3 2025, and up 3065.0% year-over-year from 1.15% in Q4 2024.
BioLineRx (BLRX) has 13 years of Return on Capital Employed data on file, last reported at 36.44% in Q4 2025.
- In Q4 2025, Return on Capital Employed rose 3065.0% year-over-year to 36.44%; the TTM figure through Dec 2025 stood at 36.44% (up 3065.0% YoY), while the FY2025 annual figure was 37.03%, up 1965.0% from the prior year.
- Return on Capital Employed advanced to 36.44% in Q4 2025, from 40.65% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 28.99% in Q2 2021 and bottomed at 318.43% in Q4 2023.
- A 5-year average of 75.88% and a median of 47.47% in 2022 frame the typical range for Return on Capital Employed.
- Annual changes were most pronounced in 2023 — Return on Capital Employed tumbled 27577 bps — and 2024, when it jumped 25134 bps.
- Year by year, Return on Capital Employed stood at 33.29% in 2021, then declined by 28 bps to 42.66% in 2022, then plunged by 646 bps to 318.43% in 2023, then soared by 79 bps to 67.09% in 2024, then surged by 46 bps to 36.44% in 2025.
- The last three Return on Capital Employed figures came in at 36.44% (Q4 2025), 40.65% (Q3 2025), and 51.98% (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | -36.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -36.44% |
| Sep 30, 2025 | -40.65% |
| Jun 30, 2025 | -51.98% |
| Mar 31, 2025 | -66.15% |
| Dec 31, 2024 | -67.09% |
| Sep 30, 2024 | -102.50% |
| Jun 30, 2024 | -150.53% |
| Mar 31, 2024 | -173.02% |
| Dec 31, 2023 | -318.43% |
| Sep 30, 2023 | -96.01% |
| Jun 30, 2023 | -66.70% |
| Mar 31, 2023 | -52.81% |
| Dec 31, 2022 | -42.66% |
| Sep 30, 2022 | -41.06% |
| Jun 30, 2022 | -42.96% |
| Mar 31, 2022 | -36.83% |
| Dec 31, 2021 | -33.29% |
| Sep 30, 2021 | -30.52% |
| Jun 30, 2021 | -28.99% |
| Mar 31, 2021 | -38.99% |
| Dec 31, 2020 | -63.64% |
| Sep 30, 2020 | -67.80% |
| Jun 30, 2020 | -74.20% |
| Mar 31, 2020 | -76.09% |
| Dec 31, 2019 | -64.73% |
| Sep 30, 2019 | -51.99% |
| Jun 30, 2019 | -45.01% |
| Mar 31, 2019 | -45.66% |
| Dec 31, 2018 | -57.45% |
| Sep 30, 2018 | -59.16% |
| Jun 30, 2018 | -55.53% |
| Mar 31, 2018 | -50.76% |
| Dec 31, 2017 | -44.42% |
| Sep 30, 2017 | -37.14% |
| Jun 30, 2017 | -41.50% |
| Mar 31, 2017 | -51.76% |
| Dec 31, 2016 | -44.70% |
| Sep 30, 2016 | -39.96% |
| Jun 30, 2016 | -34.48% |
| Mar 31, 2016 | -32.89% |
| Dec 31, 2015 | -32.37% |
| Sep 30, 2015 | -32.57% |
| Jun 30, 2015 | -32.32% |
| Mar 31, 2015 | -39.88% |
| Dec 31, 2014 | -56.32% |
| Sep 30, 2014 | -47.31% |
| Jun 30, 2014 | -39.48% |
| Mar 31, 2014 | -54.10% |
| Dec 31, 2013 | -92.14% |